Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Biotechnologijos

Mr. John G. Cox M.B.A.

Chief Executive Officer, President & Director

Ms. Kate  Mitchell

Vice President & Head of Human Resources

Dr. Romesh  Subramanian Ph.D.

Co-Founder & Advisor

Mr. John  Najim M.B.A.

Chief Technical Officer

Dr. Oxana  Beskrovnaya Ph.D.

Chief Scientific Officer

Mr. Richard William Scalzo M.B.A.

Senior Vice President and Head of Finance & Administration

Ms. Amy  Reilly

Senior Vice President and Head of Corporate Communications & Investor Relations

Mr. Daniel  Wilson

Senior Vice President & Head of Legal

Dr. Jonathan  McNeill M.D.

Chief Business Officer

Ms. Susanna Gatti High M.B.A.

Chief Operating Officer

Pavadinimas	Rinkos kapitalizacija
Sorrento Therapeutics, Inc.	0M
Maravai LifeSciences Holdings, Inc.	0M
Comera Life Sciences Holdings, Inc.	0M
Gubra A/S	0M
CytoTools AG	0M
Hofseth BioCare ASA	0M
Shanghai Haohai Biological Technology Co., Ltd.	0M
Purple Biotech Ltd.	0M

Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc. Konkurentų sąrašas

Pagrindiniai konkurentai